title: [Prophylactic intravesical BCG for bladder tumor after surgery of upper tract urothelial carcinoma].
abstract: We report the result of prophylactic intravesical instillation of BCG after surgery of upper tract urothelial carcinoma. The BCG Tokyo 172 strain was given preoperatively and/or postoperatively, as a rule, in a dose of 80 mg in 30 ml saline instilled into the bladder. Only one (14.3%) of the 7 patients with intravesical BCG developed bladder tumor at 14 month after surgery, while (45.4%) of 11 patients who did not receive intravesical BCG suffered from bladder tumor within 2 years after surgery. Prophylactic intravesical instillation of BCG reduced significantly (p less than 0.005) the recurrence of bladder tumor after the surgery of renal pelvis and ureteral tumor.
authors.affiliation: Department of Urology, Hirosaki University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Kudoh
authors.forename: F
authors.initials: F
authors.lastname: Motomura
authors.forename: F
authors.initials: F
authors.lastname: Saitoh
authors.forename: T
authors.initials: T
authors.lastname: Kogawa
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000517:prevention & control / Q000601:surgery*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery*; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014516:Ureteral Neoplasms / Q000601:surgery*; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine